Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA
The idea that you can drug RNA has attracted a variety of biotech startups interested in pioneering a new technology. And one of those biotechs looking to break new ground in the field just scooped up a $30 million round.
The Durham, NC-based biotech Ribometrix is the brainchild of Kevin Weeks, the UNC investigator who hatched the scientific ideas that would go on to create the platform at Ribometrix.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.